Survival Analysis Based on Clinicopathological Data from a Single Institution: Chemotherapy Intensity Would Be Enhanced in Patients with Positive Hormone Receptors and Positive HER2 in China Who Cannot Afford the Target Therapy
Table 2
Parameters of patients (grouping by the clinicopathological subtypes).
Parameters
Luminal A ()
Luminal B ()
HER2+ ()
TNBC ()
Statistics ( or )
Age (years)
0.838
0.475
Mean
Range
29~82
35~75
2~71
25~70
Menopause
2.119
0.548
Yes
26
24
7
21
No
40
31
19
31
Family history
1.063
0.786
No
53
47
20
42
Cancer
9
6
4
9
Breast cancer
4
2
2
1
Quadrant
7.663
0.054
Areolar
5
1
4
1
Outer upper
40
31
18
34
Outer lower
8
12
1
5
Inner lower
4
4
2
4
Inner upper
9
7
1
8
Operation
4.088
0.252
Mastectomy
62
50
21
48
Tumorectomy
4
5
5
4
Diameter
1.566
0.199
Histological grade
17.209
0.001
I
17
4
4
9
II
46
43
15
22
III
3
8
7
21
Node metastasis
3.664
0.300
Yes
24
29
10
24
No
42
26
16
28
Cancer thrombosis
4.291
0.232
Yes
16
21
11
15
No
50
34
15
37
P53
6.865
0.076
Negative
33
18
15
28
Positive
33
37
11
24
Clinical stage
4.755
0.191
I
25
13
11
16
IIA
25
20
5
16
IIB
9
8
2
7
IIIA
4
11
4
7
IIIB
0
0
0
0
IIIC
3
3
4
6
IV
0
0
0
0
Chemotherapy
11.395
0.010
No
9
1
1
0
Adjuvant
54
52
20
48
Neoadjuvant
3
2
5
4
Program
15.533
0.001
No
9 (13.6%)
1 (1.8%)
1 (3.8%)
0 (0%)
CMF
3 (4.5%)
2 (3.6%)
0 (0%)
2 (3.8%)
CAF or AC
9 (13.6%)
5 (9.1%)
0 (0%)
7 (13.5%)
CEF or EC
25 (37.9%)
37 (67.3%)
14 (53.8%)
11 (21.2%)
TC or TP
8 (12.1%)
7 (12.7%)
9 (34.6%)
18 (34.6%)
TAC or A-T
12 (18.2%)
3 (5.5%)
2 (7.7%)
14 (26.9%)
Cycle
2.784
0.042
Radiotherapy
9.552
0.023
No
47
27
11
27
Yes
19
28
15
25
Endocrine therapy
155.813
0.000
No
5
1
26
52
TAM
50
42
0
0
AI
11
12
0
0
Illustration: the ages, diameter of tumor, and chemotherapy cycle were metric data and examined by ANVOA analysis; other digital parameters were examined by test.
